Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascana in Raynaud's Phenomenon
NCT00934427Phase 3Unknown
- Sponsor
- MediQuest Therapeutics
- Start
- Jun 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MQX-503 in Raynaud's phenomenon (RP), sponsored by MediQuest Therapeutics. Status: unknown.
02
Drugs
MQX-503
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT00934427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00934427.